Versartis, Inc. (NASDAQ:VSAR) has been assigned an average rating of “Buy” from the ten research firms that are covering the stock, Marketbeat reports. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $29.43.

A number of brokerages have commented on VSAR. Canaccord Genuity set a $28.00 price objective on Versartis and gave the stock a “buy” rating in a research note on Sunday, May 28th. ValuEngine cut Versartis from a “hold” rating to a “sell” rating in a research note on Thursday, August 17th. BidaskClub cut Versartis from a “buy” rating to a “hold” rating in a research note on Sunday, July 16th. Cowen and Company restated an “outperform” rating and set a $45.00 price objective on shares of Versartis in a research note on Wednesday, August 23rd. Finally, Zacks Investment Research upgraded Versartis from a “sell” rating to a “hold” rating in a research note on Wednesday, August 30th.

Large investors have recently added to or reduced their stakes in the stock. Credit Suisse AG lifted its stake in shares of Versartis by 28.0% in the first quarter. Credit Suisse AG now owns 27,066 shares of the biopharmaceutical company’s stock worth $576,000 after acquiring an additional 5,917 shares in the last quarter. Sphera Funds Management LTD. lifted its stake in shares of Versartis by 20.0% in the first quarter. Sphera Funds Management LTD. now owns 300,000 shares of the biopharmaceutical company’s stock worth $6,405,000 after acquiring an additional 50,000 shares in the last quarter. Victory Capital Management Inc. acquired a new position in shares of Versartis in the first quarter worth about $563,000. Vanguard Group Inc. lifted its stake in shares of Versartis by 11.3% in the first quarter. Vanguard Group Inc. now owns 1,002,507 shares of the biopharmaceutical company’s stock worth $21,404,000 after acquiring an additional 101,578 shares in the last quarter. Finally, Perceptive Advisors LLC lifted its stake in shares of Versartis by 6.1% in the first quarter. Perceptive Advisors LLC now owns 4,407,317 shares of the biopharmaceutical company’s stock worth $94,096,000 after acquiring an additional 253,632 shares in the last quarter. Institutional investors and hedge funds own 78.77% of the company’s stock.

Shares of Versartis (NASDAQ:VSAR) traded down 4.77% during midday trading on Tuesday, reaching $19.95. The company’s stock had a trading volume of 416,587 shares. Versartis has a 52 week low of $9.05 and a 52 week high of $24.00. The firm’s 50 day moving average is $18.35 and its 200 day moving average is $18.51. The firm’s market capitalization is $709.78 million.

Versartis (NASDAQ:VSAR) last issued its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported ($1.04) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.84) by $0.20. Equities analysts forecast that Versartis will post ($3.49) EPS for the current fiscal year.

WARNING: This report was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another website, it was stolen and republished in violation of United States & international trademark and copyright legislation. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/09/10/versartis-inc-vsar-receives-consensus-rating-of-buy-from-analysts.html.

Versartis Company Profile

Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.

Analyst Recommendations for Versartis (NASDAQ:VSAR)

Receive News & Stock Ratings for Versartis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis Inc. and related stocks with our FREE daily email newsletter.